Skip to main content
. 2023 May 24;7(18):5246–5257. doi: 10.1182/bloodadvances.2022009067

Figure 1.

Figure 1.

Protocol scheme, dosage, and schedule. The figure represents the scheme of the protocol, consisting of 3 phases: 28 days of mono vemurafenib induction, 3 courses of Ara-C + 2-CdA with continuous vemurafenib therapy and 3 courses of mono 2-CdA. The points of cfDNA and myeloid precursor population ddPCR analysis are also marked accordingly.